Anika Therapeutics, Inc.(ANIK)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Anika Therapeutics, Inc. (ANIK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIK at 34.4/100 on a 32-signal composite quality model, placing it at rank #2,349 of 2,960 stocks — the bottom half of the AI-ranked universe. ANIK scores in the top quartile across earnings quality (76.3). Areas of concern include institutional flow (15.9) and revenue scale (18.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Anika Therapeutics, Inc. reports quarterly revenue of $32.6M, net income of $3.3M, free cash flow of $-2.1M. Top institutional holders of ANIK by reported 13-F value include BlackRock, Caligan Partners, MORGAN STANLEY, based on the most recent SEC filings. ANIK trades on the Nasdaq exchange and files with the SEC under CIK 898437. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anika Therapeutics, Inc. directly from SEC EDGAR.